Ustekinumab for the Treatment of Giant Cell Arteritis

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02955147
• Date of registration: 31/10/2016
• Prospective Registration: Yes
• Primary sponsor: Massachusetts General Hospital
• Public title: Ustekinumab for the Treatment of Giant Cell Arteritis UGCA
• Scientific title: Open Label Study to Test the Safety and Efficacy of Ustekinumab in Patients With Giant Cell Arteritis
• Date of first enrolment: December 1, 2016
• Target sample size: 13
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT02955147
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1/Phase 2

Countries of recruitment

United States

Key inclusion & exclusion criteria

Inclusion Criteria: Subjects must meet the following criteria

1. Able and willing to provide written informed consent and to comply with the study
protocol

2. Diagnosis of GCA classified according to the following criteria:

- Age 50 years or older

- History of erythrosedimentation rate (ESR) = 50 mm/hour or C-reactive protein
(CRP) = 10 mg/L

AND at least one of the following:

- Cranial symptoms of GCA

- Symptoms of polymyalgia rheumatica (PMR)

AND at least one of the following:

- Temporal artery biopsy revealing features of GCA

- Evidence of large-vessel vasculitis by angiography or cross-sectional imaging

3. Active new-onset or relapsing active disease

Exclusion Criteria:

1. Allergies: Subjects who have history of previous severe allergic or anaphylactic
reaction associated with the administration of monoclonal antibodies or antibody
fragments.

2. Systemic infection: Subjects who have an active systemic infection.

3. Serious infection: Subjects who have had serious infections, or any major episode of
infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of
enrollment.

4. Chronic or recurrent infection: Subjects who have chronic or recurrent bacterial,
viral, fungal, mycobacterial, or protozoan infection.

5. Opportunistic infection: Subjects who have, or have had, an opportunistic infection
within 6 months prior to enrollment.

6. Subjects who have active hepatitis B or active hepatitis C or a documented history of
HIV

7. Latent tuberculosis infection

8. Malignancy

9. Subjects with evidence of serious uncontrolled concomitant cardiovascular, nervous
system, pulmonary, renal, hepatic, endocrine, immunologic, psychiatric or
gastrointestinal disease that could interfere with participation in the trial
according to the protocol.

10. Subjects with transplanted organs (with the exception of a corneal transplant > 3
months prior to screening)

11. Major surgery within 8 weeks prior to Screening or planned major surgery within 12
months after Baseline

12. Pregnancy

13. The following laboratory abnormalities

- Hemoglobin < 8 gr/dL

- Platelets < 100/mm3

- White blood cell count (WBC) < 3000/mm3

- Absolute neutrophil count < 2000/mm3

- Absolute lymphocyte count < 500/mm3

- Serum creatinine > 1.4 mg/dL in female subjects and > 1.6 mg/dL in male subjects

- Total bilirubin > 2 mg/dL

- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 X upper
limit of normal

- Positive hepatitis B surface antigen, hepatitis B core antibody or hepatitis C
antibody

14. Prohibited medications:

- Subjects who received methotrexate (MTX) > 30 mg weekly, azathioprine,
mycophenolate mofetil, cyclophosphamide, chlorambucil, tacrolimus, leflunomide,
canakinumab, belimumab, abatacept, tocilizumab, secukinumab, infliximab,
etanercept, adalimumab, golimumab, or certolizumab within the 3-month period
prior to enrollment.

- Subjects who had treatment with any anti-cluster designation antigen (CD)20 agent
(e.g., rituximab) within the 9-month period prior to enrolment

- Subjects who used any investigational drug within 1 month prior to enrollment or
within 5 half-lives of the investigational agent, whichever is longer.

- Low dose MTX: Patients on < 30 mg of MTX weekly will be eligible for enrollment
after a 2-week washout interval before receiving ustekinumab

- Vaccines: Subjects who received any live virus or bacterial vaccinations other
than bacille Calmette-Guerin (BCG) within the 3 months before the first
administration of the study agent, or are expected to receive any live virus or
live bacterial vaccinations during the study, or up to 3 month after the last
administration of ustekinumab are not eligible. Subjects who received BCG
vaccines within the 12 months before the first administration of the study agent,
or are expected to receive BCG vaccines during the study, or up to 12 month after
the last administration of ustekinumab are also not eligible.



Age minimum: 50 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Temporal Arteritis

Horton's Disease

Giant Cell Arteritis

Intervention(s)

Drug: Prednisone

Drug: Ustekinumab

Primary Outcome(s)

Percentage of Patients in Glucocorticoid-free Remission [Time Frame: 52 weeks]

Secondary Outcome(s)

Cumulative Prednisone Dose [Time Frame: 52 weeks]

Number of Participants With Disease Flare [Time Frame: 52 weeks]

Secondary ID(s)

2016P000932

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 12/06/2020
• URL: https://clinicaltrials.gov/ct2/show/results/NCT02955147